KalVista Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of KalVista Pharmaceuticals generated cash of -$89,231,000, which is less than the previous year. Cash used in financing activities reached the amount of $150,714,000 last year. Net change in cash is therefore -$24,449,000.
Cash Flow
| 2015 | -6.36M | -125K | 8.66M |
|---|---|---|---|
| 2016 | -13.15M | -11K | 33.00M |
| 2017 | -23.72M | 34.06M | 2K |
| 2018 | 10.55M | -1.42M | 8.98M |
| 2019 | -36.36M | -69.42M | 87.94M |
| 2020 | -44.81M | 16.75M | 11.58M |
| 2021 | -30.17M | -147.65M | 212.11M |
| 2022 | -78.13M | 57.86M | 1.58M |
| 2023 | -75.26M | 41.41M | 58.11M |
| 2024 | -89.23M | -84.71M | 150.71M |
KALV Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 56.23M | 30.73M | 50.59M | 15.78M | 32.00M | 51.05M | 30.95M | 21.76M | 2.52M | 481K |
Operating activities | ||||||||||
Net income | -126.64M | -92.90M | -82.33M | -46.24M | -29.11M | -20.81M | -15.80M | -18.60M | -11.43M | -7.22M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 816K | 718K | 564K | 537K | 512K | 378K | 180K | 40K | 33K | 38K |
Stock-based compensation expense | 21.91M | 9.92M | 11.08M | 7.11M | 4.44M | 2.96M | 0 | 394K | 118K | 36K |
| Deferred income tax benefit | 21.91M | 9.92M | 11.08M | 7.11M | 4.44M | 2.96M | 0 | 394K | 118K | 36K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 8.17M | -2.31M | -5.20M | 7.45M | -5.78M | -4.88M | -3.93M | -571K | -137 | 65 |
Inventories | 0 | 2.31M | 5.20M | -7.45M | 5.78M | 4.88M | 0 | 0 | 0 | 0 |
Accounts payable | 4.32M | 1.10M | 1.68M | 150K | -1.00M | 1.53M | 217K | -1.59M | 374K | 167K |
Cash generated by operating activities | -89.23M | -75.26M | -78.13M | -30.17M | -44.81M | -36.36M | 10.55M | -23.72M | -13.15M | -6.36M |
Investing activities | ||||||||||
Purchases Of Investments | -189.23M | -98.24M | -136.92M | -201.21M | -49.79M | -79.88M | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -1.19M | -931K | -82K | -220K | -1.08M | -1.42M | -74K | -11K | -125K |
Acquisitions Net | 0 | -57.86M | -57.86M | 147.65M | -16.75M | 69.42M | 0 | 34.13M | 0 | 0 |
Cash generated by investing activities | -84.71M | 41.41M | 57.86M | -147.65M | 16.75M | -69.42M | -1.42M | 34.06M | -11K | -125K |
Financing activities | ||||||||||
Common Stock Issued | 96.94M | 56.58M | 1.58M | 210.58M | 11.42M | 87.91M | 9.13M | 2K | 1K | 1K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | -54K | -209K | -151K | 0 | -4M | 0 |
Cash used in financing activities | 150.71M | 58.11M | 1.58M | 212.11M | 11.58M | 87.94M | 8.98M | 2K | 33.00M | 8.66M |
Net Change In Cash | -24.44M | 25.50M | -19.86M | 34.80M | -16.21M | -19.04M | 20.10M | 9.18M | 19.23M | 2.04M |
Cash at end of period | 31.78M | 56.23M | 30.73M | 50.59M | 15.78M | 32.00M | 51.05M | 30.95M | 21.76M | 2.52M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |